CN116710446B - Glp-1r激动剂的晶型及其用途 - Google Patents

Glp-1r激动剂的晶型及其用途 Download PDF

Info

Publication number
CN116710446B
CN116710446B CN202180082321.9A CN202180082321A CN116710446B CN 116710446 B CN116710446 B CN 116710446B CN 202180082321 A CN202180082321 A CN 202180082321A CN 116710446 B CN116710446 B CN 116710446B
Authority
CN
China
Prior art keywords
disease
compound
crystalline form
diabetes
condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180082321.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN116710446A (zh
Inventor
钟文革
郭巍
Z·J·李
姜夏伟
陈鹏源
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Qilu Ruige Pharmaceutical R & D Co ltd
Original Assignee
Shanghai Qilu Ruige Pharmaceutical R & D Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Qilu Ruige Pharmaceutical R & D Co ltd filed Critical Shanghai Qilu Ruige Pharmaceutical R & D Co ltd
Publication of CN116710446A publication Critical patent/CN116710446A/zh
Application granted granted Critical
Publication of CN116710446B publication Critical patent/CN116710446B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN202180082321.9A 2020-10-14 2021-10-13 Glp-1r激动剂的晶型及其用途 Active CN116710446B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020120814 2020-10-14
CNPCT/CN2020/120814 2020-10-14
PCT/CN2021/123387 WO2022078352A1 (en) 2020-10-14 2021-10-13 Crystal forms of glp-1r agonists and uses thereof

Publications (2)

Publication Number Publication Date
CN116710446A CN116710446A (zh) 2023-09-05
CN116710446B true CN116710446B (zh) 2024-10-18

Family

ID=78401981

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180082321.9A Active CN116710446B (zh) 2020-10-14 2021-10-13 Glp-1r激动剂的晶型及其用途

Country Status (9)

Country Link
US (1) US12516041B2 (https=)
EP (1) EP4228753B1 (https=)
JP (1) JP7769695B2 (https=)
CN (1) CN116710446B (https=)
AU (1) AU2021359493A1 (https=)
CA (1) CA3195264A1 (https=)
ES (1) ES3041328T3 (https=)
TW (1) TWI912388B (https=)
WO (1) WO2022078352A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210069000A (ko) * 2019-12-02 2021-06-10 현대약품 주식회사 Glp-1 수용체 작용제
KR20240068737A (ko) 2021-09-27 2024-05-17 테른스 파마슈티칼스, 인크. Glp-1r 효능제로서의 벤즈이미다졸 카복실산
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
KR20240150488A (ko) 2022-02-23 2024-10-15 테른스 파마슈티칼스, 인크. Glp-1r 작용제로서의 화합물
CN117362282B (zh) * 2022-07-07 2026-04-21 杭州德睿智药科技有限公司 Glp-1r激动剂的盐及其制备方法和应用
AU2023310481A1 (en) * 2022-07-18 2025-03-06 Mindrank Therapeutics (Suzhou) New Drug Research And Development Co., Ltd Polymorphic form of glp-1r agonist, preparation method therefor and use thereof
US20240398794A1 (en) 2023-04-07 2024-12-05 Terns Pharmaceuticals, Inc. COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF
TW202521533A (zh) 2023-09-14 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106109469A (zh) * 2010-11-15 2016-11-16 贝林格尔·英格海姆国际有限公司 保护血管及保护心脏的抗糖尿病性治疗
WO2019239371A1 (en) * 2018-06-15 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US7727983B2 (en) 2008-03-07 2010-06-01 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
EP3555064B9 (en) * 2016-12-16 2023-03-01 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CR20210341A (es) * 2018-11-22 2021-11-25 Qilu Regor Therapeutics Inc Agonistas de glp-ir y usos de los mismos
US10954221B2 (en) * 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
AU2020256647B2 (en) * 2019-04-12 2025-07-31 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106109469A (zh) * 2010-11-15 2016-11-16 贝林格尔·英格海姆国际有限公司 保护血管及保护心脏的抗糖尿病性治疗
WO2019239371A1 (en) * 2018-06-15 2019-12-19 Pfizer Inc. Glp-1 receptor agonists and uses thereof

Also Published As

Publication number Publication date
EP4228753C0 (en) 2025-07-30
JP2023546125A (ja) 2023-11-01
ES3041328T3 (en) 2025-11-11
EP4228753B1 (en) 2025-07-30
US12516041B2 (en) 2026-01-06
WO2022078352A1 (en) 2022-04-21
CA3195264A1 (en) 2022-04-21
AU2021359493A9 (en) 2025-01-09
US20230382899A1 (en) 2023-11-30
CN116710446A (zh) 2023-09-05
TWI912388B (zh) 2026-01-21
JP7769695B2 (ja) 2025-11-13
AU2021359493A1 (en) 2023-06-15
TW202227421A (zh) 2022-07-16
EP4228753A1 (en) 2023-08-23

Similar Documents

Publication Publication Date Title
CN116710446B (zh) Glp-1r激动剂的晶型及其用途
JP7702973B2 (ja) Ｇｌｐ－１ｒアゴニストの塩及び結晶形態、並びにそれらの使用
TWI839416B (zh) Ｇｌｐ-１ｒ促效劑及其用途
TWI809334B (zh) ２－（（４－（（Ｓ）－２－（５－氯吡啶－２－基）－２－甲基苯并〔ｄ〕〔１，３〕二氧呃－４－基）哌啶－１－基）甲基）－１－（（（Ｓ）－氧呾－２－基）甲基）－１Ｈ－苯并〔ｄ〕咪唑－６－羧酸１，３－二羥基－２－（羥基甲基）丙烷－２－胺鹽之固體形式
TW202214622A (zh) Ｇｌｐ－１ｒ促效劑及其用途
TWI840348B (zh) G蛋白偶聯受體調節劑
US12410163B2 (en) Compounds as GLP-IR agonists
CN118401519A (zh) 作为glp-1r激动剂的化合物
HK40089377B (en) Crystal forms of glp-1r agonists and uses thereof
HK40089377A (en) Crystal forms of glp-1r agonists and uses thereof
TWI913272B (zh) Ｇｌｐ-１ｒ促效劑之鹽和晶型及其用途
HK40087545A (en) Salt and crystal forms of glp-1r agonists and uses thereof
HK40087545B (en) Salt and crystal forms of glp-1r agonists and uses thereof
CN104926706B (zh) 六氢并环戊二烯衍生物的盐及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant